Atezolizumab Plus Bevacizumab-induced Recalcitrant Pyoderma Gangrenosum Treated with Baricitinib: A Case Report
DOI:
https://doi.org/10.2340/actadv.v103.9646Keywords:
pyoderma gangrenosum, atezolizumab, bevacizumab, janus kinase inhibitor, baricitinibAbstract
Abstract is missing (Short communication)
Downloads
References
Crowson AN, Mihm MC, Jr, Magro C. Pyoderma gangrenosum: a review. J Cutan Pathol 2003; 30: 97-107.
https://doi.org/10.1034/j.1600-0560.2003.00024.x DOI: https://doi.org/10.1034/j.1600-0560.2003.00024.x
Ahn C, Negus D, Huang W. Pyoderma gangrenosum: a review of pathogenesis and treatment. Expert Rev Clin Immunol 2018; 14: 225-233.
https://doi.org/10.1080/1744666X.2018.1438269 DOI: https://doi.org/10.1080/1744666X.2018.1438269
Wu BC, Patel ED, Ortega-Loayza AG. Drug-induced pyoderma gangrenosum: a model to understand the pathogenesis of pyoderma gangrenosum. Br J Dermatol 2017; 177: 72-83.
https://doi.org/10.1111/bjd.15193 DOI: https://doi.org/10.1111/bjd.15193
Tsibris H, Lian C, Ho A. Pembrolizumab-associated pyoderma gangrenosum in a patient with metastatic squamous cell carcinoma. Dermatol Online J 2021; 27.
https://doi.org/10.5070/D3274053158 DOI: https://doi.org/10.5070/D3274053158
Rudolph BM, Staib F, Von Stebut E, Hainz M, Grabbe S, Loquai C. Neutrophilic disease of the skin and intestines after ipilimumab treatment for malignant melanoma - simultaneous occurrence of pyoderma gangrenosum and colitis. Eur J Dermatol 2014; 24: 268-269.
https://doi.org/10.1684/ejd.2014.2297 DOI: https://doi.org/10.1684/ejd.2014.2297
Welborn ME, Kubicki SL, Patel AB. Pyoderma gangrenosum following initiation of immune checkpoint inhibitor therapy. J Immunother Precis Oncol 2018; 1: 82-84.
https://doi.org/10.4103/JIPO.JIPO_11_18 DOI: https://doi.org/10.4103/JIPO.JIPO_11_18
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 2020; 382: 1894-1905.
https://doi.org/10.1056/NEJMoa1915745 DOI: https://doi.org/10.1056/NEJMoa1915745
Ellis SR, Vierra AT, Millsop JW, Lacouture ME, Kiuru M. Dermatologic toxicities to immune checkpoint inhibitor therapy: a review of histopathologic features. J Am Acad Dermatol 2020; 83: 1130-1143.
https://doi.org/10.1016/j.jaad.2020.04.105 DOI: https://doi.org/10.1016/j.jaad.2020.04.105
Ellis C, M. M, LaFond A, Fivenson D. An interesting case of pyoderma gangrenosum. J Am Acad Dermatol 2016; 74.
https://doi.org/10.1016/j.jaad.2016.02.1127 DOI: https://doi.org/10.1016/j.jaad.2016.02.1127
Akanay-Diesel S, Hoff NP, Kurle S, Haes J, Erhardt A, Haussinger D, et al. Sunitinib induced pyoderma gangrenosum-like ulcerations. Eur J Med Res 2011; 16: 491-494.
https://doi.org/10.1186/2047-783X-16-11-491 DOI: https://doi.org/10.1186/2047-783X-16-11-491
Scheinberg M, Machado LA, LG MC, Ferreira SB, Michalany N. Successful treatment of ulcerated pyoderma gangrenosum with baricitinib, a novel JAK inhibitor. J Transl Autoimmun 2021; 4: 100099.
https://doi.org/10.1016/j.jtauto.2021.100099 DOI: https://doi.org/10.1016/j.jtauto.2021.100099
Sitaru S, Biedermann T, Lauffer F. Successful treatment of pyoderma gangrenosum with Janus kinase 1/2 inhibition. JEADV Clinical Practice 2022; 1: 420-423.
https://doi.org/10.1002/jvc2.62 DOI: https://doi.org/10.1002/jvc2.62
Ortega-Loayza AG, Friedman MA, Reese AM, Liu Y, Greiling TM, Cassidy PB, et al. Molecular and cellular characterization of pyoderma gangrenosum: implications for the use of gene expression. J Invest Dermatol 2022; 142: 1217-1220.e4.
https://doi.org/10.1016/j.jid.2021.08.431 DOI: https://doi.org/10.1016/j.jid.2021.08.431
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Han Seul Kim, Ji Eun Kwon, Young Joon Park
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
